canertinib dihydrochloride has been researched along with 2019 Novel Coronavirus Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aggarwal, R; Belsey, JD; Brack, K; Bulle, A; Chen, Z; Fluck, D; John, I; Kodre, A; Kralj-Hans, I; Lamorgese, A; Li, HL; Li, K; Li, L; Li, S; Marczin, N; McGee, M; Omar, F; Ranasinghe, K; Seshasai, SRK; Sharma, P; Sharma, S; Wesek, A | 1 |
| Chen, HH; Chen, ZJ; Xiao, J | 1 |
1 trial(s) available for canertinib dihydrochloride and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Leflunomide treatment for patients hospitalised with COVID-19: DEFEAT-COVID randomised controlled trial.
Topics: Adult; Aged; COVID-19; Female; Humans; Leflunomide; Male; Middle Aged; Oxygen; Prospective Studies; SARS-CoV-2; Treatment Outcome | 2023 |
1 other study(ies) available for canertinib dihydrochloride and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Identification of Key Genes Related to Immune Cells in Patients with COVID-19 Via Integrated Bioinformatics-Based Analysis.
Topics: Apoptosis Regulatory Proteins; Calcium-Binding Proteins; Cell Cycle; Computational Biology; COVID-19; Humans; Tumor Suppressor Protein p53 | 2023 |